Home Featured Page 194

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

PT295 – Sidarta Ribeiro – Dreams, LSD, and Biopiracy

Psychedelic Bulletin: Tracking LSD Patents; Psilocybin Effective for a Year in...

PT294 – Andrew Tatarsky, Ph.D. & Juliana Mulligan – Vital Psychedelic...

HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S....

Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access...

Trauma and Vulnerability to Suggestion: Redefining How We Understand Consent

COMPASS Pathways plc to announce fourth quarter and full year 2021...

Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through...

Awakn Files Patent For A New Class Of Entactogen-Like Molecules

Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.